Informação sobre produto
XMD16-5 is a pharmacologic drug that inhibits the activity of a number of tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR). XMD16-5 has been shown to be effective in leukemia cells. It has also been shown to inhibit the activity of BCR-ABL, an oncogenic tyrosine kinase. XMD16-5 is a multi-kinase inhibitor with targetable properties. It has been shown to have a high degree of selectivity for PDGFR and VEGFR over other kinases. This drug is being developed by Novartis as a targeted therapy for cancers with activating mutations in these two receptors.
Propriedades químicas
Consulta técnica sobre: 3D-VDC09878 XMD16-5
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
